Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$209.34 USD

209.34
599,679

+3.38 (1.64%)

Updated May 30, 2024 04:00 PM ET

After-Market: $209.34 0.00 (0.00%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth

ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.

    Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up

    Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.

      LabCorp (LH) Beats on Q1 Earnings, Revenues, Lifts '18 View

      LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.

        Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up

        Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.

          Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance

          Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.

            Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss

            Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.

              Medical Product Stock Earnings Roster for Apr 26: BAX & More

              Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.

                Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View

                Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.

                  Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?

                  ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.

                    Global Expansion and Product Launches to Aid ResMed's Growth

                    ResMed (RMD) continues to benefit from solid sales of sleep devices, respiratory care devices, mask systems and software solutions globally.

                      Here's Why You Must Add ResMed (RMD) to Your Portfolio Now

                      ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.

                        ResMed (RMD) Rides High on Robust Global Growth & Innovation

                        ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.

                          Why Is ResMed (RMD) Down 7.5% Since the Last Earnings Report?

                          ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up

                            Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.

                              LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising

                              LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.

                                Align Technology Banks on Global Growth, Competition Rife

                                We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.

                                  Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

                                  Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.

                                    IDEXX Laboratories Strong on CAG Business Amid Currency Woes

                                    IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.

                                      Hill-Rom (HRC) Trades on Product Innovation, Competition Rife

                                      Hill-Rom (HRC) focuses on product innovation, the latest launch being Connex Cardio ECG.

                                        Integra LifeSciences Global Prospects Solid, Competition Rife

                                        Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.

                                          Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues

                                          Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.

                                            Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

                                            Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.

                                              Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales

                                              Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.

                                                Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)

                                                Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.

                                                  Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?

                                                  Abaxis (ABAX) rides high on recently received approval from USDA.